A carregar...

Perspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma

The NAD(+)-metabolizing ectoenzyme CD38 is an established therapeutic target in multiple myeloma. The CD38-specific monoclonal antibodies daratumumab and isatuximab show promising results in the clinic. Nanobodies correspond to the single variable domains (VHH) derived from heavy chain antibodies th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Immunol
Main Authors: Bannas, Peter, Koch-Nolte, Friedrich
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2018
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6232533/
https://ncbi.nlm.nih.gov/pubmed/30459772
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2018.02559
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!